Skip to content

    Thyrocare Tech.

    THYROCAREGood
    Healthcare·23 Apr 2025
    Management Summary

    Thyrocare Technologies reported strong Q4 and full-year FY25 results, driven by robust growth across its Pathology, Franchisee, and Partnership businesses. The company achieved significant margin expansion in Q4 due to better product mix, operating leverage, and reduced doubtful debt provisioning. Strategic initiatives like network expansion, selective acquisitions, and enhanced service offerings, including ECG at home, contributed to its outperformance in the diagnostic industry.

    Highlights

    8

    • Consolidated revenue for FY25 reached INR687 crores, reflecting a robust 20% year-on-year growth.

    • Q4 FY25 saw a 21% year-on-year revenue growth, primarily driven by Pathology business (23% YoY).

    • Full year FY25 normalized EBITDA stood at INR210 crores, with a normalized EBITDA margin of 31%.

    • Q4 FY25 stand-alone normalized EBITDA margin was 36%, an increase of 1,026 basis points.

    • Test volume grew by 14% year-on-year to 167.9 million tests, serving 16.7 million patients (up 11% YoY).

    • The company recommended a final dividend of INR21 per equity share for FY25.

    • Operating cash flow for FY25 was INR191 crores, significantly exceeding annual capex of INR40-50 crores.

    • Active franchisee network expanded to over 11,000, with plans to add 1,500+ new partners in the coming year.

    Key financials

    Metrics

    8

    Periods

    3

    Headline

    6
    • Consolidated Revenue
      ₹687 Cr
      YoY+20%
    • Stand-alone Revenue
      ₹633 Cr
    • Normalized EBITDA
      ₹210 Cr
    • PAT (excl. DTA reversal)
      ₹101 Cr
      YoY+45%
    • Operating Cash Flow
      ₹191 Cr

    Q4 FY25

    1
    • Normalized EBITDA Margin
      35%
      YoY+10.3%

    FY25

    1
    • Normalized EBITDA Margin
      31%

    Segment breakdown

    Revenue Growth (FY25)Revenue Growth (Q4 FY25)
    Pathology Business21%23%
    Radiology Business14.0%17%
    Franchisee Business18%22%
    Partnership Business27%24%
    Partnership Business (excl. API)36%40%
    API PharmEasy Diagnostics11%—
    Aarogyam Business——
    Heatmap· 2 shared metrics

    Guidance & targets

    7
    CategoryTargetPriority
    Revenue
    Revenue Growth
    mid-teens
    		Medium
    Profitability
    Full Year Normalized EBITDA Margin
    31%
    		Medium
    Volume
    Volume Growth
    similar to price growth
    		Medium
    Headcount
    New Franchisee Partners
    upwards of 1,500
    		High
    Capex
    Acquisition Spend
    INR15-20 crores
    		High
    Tax
    Effective Tax Rate
    28-29%
    		High
    Test Menu
    New Technologies
    allergy and genomics
    		High

    Risks & concerns

    5
    RiskSeverity

    Competitive Pricing Pressure

    Management noted that competitors might respond with price reductions as Thyrocare gains market share, potentially impacting future revenue growth. — Management acknowledged

    medium

    Acquisition Integration Challenges

    The acquisition of Vimta is currently in transition and expected to integrate in the next 3 months, indicating potential short-term operational challenges. — Management acknowledged

    medium

    Management Bandwidth for Acquisitions

    Management stated that acquisitions, regardless of size, consume substantial management bandwidth, leading to a choosy approach for future deals. — Management acknowledged

    low

    Nueclear Margin Sustainability

    While Nueclear's margins have improved, management prefers to 'wait and watch for 1 or 2 more quarters' before confirming sustainability, indicating some uncertainty. — Management acknowledged

    low

    Areas of Evasion(1)

    • PharmEasy merger status (dismissed as media speculation without further detail)

    Q&A highlights

    3

    “This is a deferred tax provision what we have made in 2019, 2020 when the investment of NHL impairment has been done... management has taken that call that the deferred tax assets provisions taken against the impairment of asset investments, what we have done is not supposed to be reversed and we have taken that call and that hit has come in the P&L as an exception item, deferred tax reversal INR11.2 crores.”

    Clarified the unusually high tax rate reported for the quarter, explaining it was a non-cash deferred tax reversal related to past NHL impairment, which significantly impacted reported PAT.

    asked by Raman Kv

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Financial Performance in FY25

    Thyrocare Technologies delivered a robust performance in FY25, with consolidated revenue growing 20% year-on-year to INR687 crores. The Pathology business was a key driver, expanding 21% for the full year and 23% in Q4 FY25. Normalized EBITDA for FY25 stood at INR210 crores, achieving a healthy 31% margin, while Q4 FY25 saw an even stronger 35% normalized EBITDA margin, an increase of 1,026 basis points year-on-year.

    02

    Drivers of Margin Expansion

    The significant 10% EBITDA margin improvement in Q4 FY25 was attributed to three main factors. Approximately 4% came from gross margin uplift due to year-end credit notes for increased volumes from vendors. Another 2% was due to operating leverage from higher growth, and the remaining 4% resulted from reduced provisioning for doubtful debts, reflecting diligent collection efforts and controlled outstanding receivables.

    03

    Network Expansion and Strategic Acquisitions

    Thyrocare expanded its active franchisee network to over 11,000, processing 167.9 million tests (up 14% YoY) and serving 16.7 million patients (up 11% YoY) in FY25. The company plans to add upwards of 1,500 new franchise partners in the coming year. Strategic acquisitions like Polo Labs and Vimta's Clinical Diagnostics business strengthened its footprint in North and South India, respectively, complementing its 'string of pearls' acquisition strategy with a planned INR15-20 crores for acquisitions in FY26.

    04

    Partnership Business and Service Enhancements

    The partnership business demonstrated strong growth, increasing 27% year-on-year for FY25 and 24% in Q4 FY25. Excluding API PharmEasy Diagnostics, this segment grew 36% for the full year and 40% in Q4. The acquisition of Think Health enhanced offerings for the insurance segment, enabling ECG at home services in over 1,000 pin codes with a dedicated fleet of 170 phlebotomists, providing a one-stop solution for partners.

    05

    Quality, Turnaround Time, and Research Initiatives

    Thyrocare emphasized its commitment to quality, being India's first and only 100% NABL accredited national laboratory chain. An independent study revealed 9 out of 10 doctors trust Thyrocare reports. The company maintained a rapid turnaround time, releasing reports within 3.43 hours of samples reaching the lab. Research initiatives under Thyrocare Anusandhan included India's largest HbA1c study (20 lakh results) and a dengue case study (1 lakh cases), providing deep insights into health trends.

    06

    Receivables Increase and Credit Policy Adjustment

    Receivables increased by approximately INR30 crores, from INR40-50 crores to INR73 crores. This was primarily due to the growth in the partnership business, where credit is typically offered. Additionally, the company extended its credit period for tech partners from 1 month to 2-3 months to align with competitive practices, contributing INR16-18 crores to the increase in receivables.

    07

    Future Outlook and Capital Allocation

    Management guided for mid-teens revenue growth in FY26, aiming to maintain the full year normalized EBITDA margin at around 31%. The effective tax rate going forward⏳ is expected to be 28-29%. With FY25 operating cash flow of INR191 crores and annual capex of INR40-50 crores, the company is cash-rich and plans to continue its dividend policy, having recommended INR21 per equity share for FY25.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.